Canada / Health Canada Medical Device Market-Entry Product Evidence Pack
From US$1,500 · 3–5 business days after scope confirmation · all prices in U.S. dollars (USD)
Before you enter the Canadian medical device market, get a source-backed view of your product family and how it compares with similar licensed devices already in the Canadian market.
TrueMedDevice prepares a structured Market-Entry Product Evidence Pack for medical device founders, manufacturers, RA/QA teams, and consultants before formal Health Canada licence application planning. We organize public evidence around direct and indirect similar-product comparison from MDALL, candidate Class I / II / III / IV clues, Health Canada forms / fees / guidance / standards, a practical preparation gap checklist, public safety-history themes, and a source ledger.
This is not regulatory, legal, or compliance advice. TrueMedDevice does not determine device class, MDL/MDEL eligibility, licence outcome, compliance, safety, or effectiveness. We prepare a source-backed Health Canada / MDALL / public-source evidence pack so qualified RA/QA professionals or regulatory consultants can review and decide.
Who this is for
- Medical device startups and founders preparing Canadian market entry
- Foreign manufacturers preparing Health Canada licence applications
- Early RA/QA teams building their first product-family knowledge base for the Canadian market
- Regulatory consultants who need a source-backed first scan of the Canadian landscape before scoping an engagement
- Product and engineering teams planning design, risk, and verification strategy before formal Health Canada submission work begins
This service is designed for teams working on product family scoping before formal Health Canada licence application planning begins — not for teams who have already filed or who need live regulatory advice.
What you get
A structured Market-Entry Product Evidence Pack organized in twelve modules, delivered as a PDF report with source ledger, similar-product comparison, preparation gap checklist, and consultant briefing sheet.
Health Canada-style product regulatory-language profile
Step 1: Build the regulator-language product-family profile.
Intended purpose, user / patient / environment, device description, indications, and technology characteristics written in Health Canada regulatory language. This is the evidence anchor for every subsequent module.
Candidate Class I / II / III / IV clues
Candidate device class clues (Class I–IV under the Medical Devices Regulations SOR/98-282), applicable licence type, and candidate medical device licence or MDEL discussion points drawn from MDALL and Health Canada records. For qualified RA/QA or consultant review — not a regulatory determination.
Direct and indirect similar-product comparison
Direct and indirect similar products from MDALL and Health Canada public records — enriched with public company websites, product pages, IFUs, manuals, brochures, labels, and publicly available technical materials where available.
Same / different comparison vs. your product
What appears similar to your product, what appears different, and publicly visible technical-characteristic differences where available. Limitations stated explicitly where public information is incomplete.
Official Health Canada forms / fees / guidance / standards checklist
Applicable Health Canada medical device licence application forms, current fee references, relevant Health Canada guidance documents, recognized Canadian and international standards, and a submission-preparation reference checklist. Verified from public Health Canada sources at pack delivery date.
Practical preparation gap checklist
Information, testing, documentation, labeling, risk, PMS, quality, and evidence categories to discuss or prepare. Plus public Health Canada review-timeline references where available.
Public safety-history scan
Recalls, Medical Device Problem Reports, advisories, incident themes, safety communications, and public field-action themes from Health Canada's Recalls and Safety Alerts database. In the last 3–5 years where relevant.
Candidate review-point library: design / risk / verification / usability / labeling / cybersecurity / PMS
Candidate review questions drawn from the safety-history scan for early design, risk management, verification & validation, usability engineering, labeling, cybersecurity, and PMS planning. For qualified review only — not compliance conclusions.
Source ledger
Record IDs, source links, access dates, and a short note on why each source matters — so any reviewer can re-walk the evidence trail. Transparent and auditable.
Consultant / RA/QA briefing sheet
A structured summary of the pack's findings, formatted for handoff to a qualified RA/QA professional or regulatory consultant.
Clear limitations and unanswered questions
A short, explicit list of what was not in scope, where public information was incomplete, and questions to bring to qualified RA/QA or consultant review.
Reusable Product Evidence Base seed
The pack also becomes the starting point for a source-backed Product Evidence Base around your product family — reused later for consultant discussions, PMS planning, complaint review, risk-file updates, labeling changes, CAPA screening, supplier signals, and inspection-readiness discussions.
Optional: follow-up Product Family Workspace and monthly public safety signal refresh available after initial pack delivery.
International manufacturers
Research packs are prepared with English as the canonical source-backed language. Companion versions in Simplified Chinese or Japanese can be requested to help internal review teams read the evidence more easily. French-language regulatory terminology for Health Canada documents is available on request. No machine-translated content is delivered without human review.
Pilot pricing
Founder-led pilot pricing — scope confirmed after a short scoping call.
First pilots are founder-led so we can understand the product context before preparing the pack. Final price and delivery timeline are confirmed after a 15–20 minute scoping call. All prices are in U.S. dollars (USD).
- U.S. / FDA Market-Entry Product Evidence Packfrom US$1,800
3–5 business days after scope confirmation
- Canada / Health Canada Market-Entry Product Evidence Packfrom US$1,500
3–5 business days after scope confirmation
- Ongoing Product Evidence Base support
Cadence and scope discussed during the scoping call.
Pilot pricing after first pack
We are currently accepting a small number of founder-led pilot customers. The goal is to understand your product context, deliver a useful first Market-Entry Product Evidence Pack, and learn whether ongoing source-backed Product Evidence Base support would help your team.
Standard scope. Standard pricing covers one product family, one jurisdiction, and one primary intended-use direction, based on non-confidential product information and public sources. Complex multi-product families, multiple intended-use directions, software-heavy products, IVDs, combination-product questions, or expanded competitor / technical comparisons are scoped separately.
Scoping calls are short and used to confirm scope, price, and delivery timeline. No payment is collected before the scoping call.
Also planning U.S. market entry?
See the U.S. / FDA Market-Entry Product Evidence PackReady to build your Canada Market-Entry Product Evidence Pack?
Share a non-confidential product description. We will help you structure the first product-family profile and confirm scope, price, and delivery timeline on a 15–20 minute scoping call before the full pack is prepared.
TrueMedDevice does not determine final classification, pathway, licence eligibility, substantial equivalence, safety, effectiveness, compliance, approval likelihood, or regulatory outcome. We prepare source-backed evidence, source ledgers, candidate review points, and briefing materials to support qualified RA/QA, consultant, and company review. Evidence organized. Judgment stays with RA/QA.
What should I research before a Health Canada medical device licence or consultant conversation?
Before the first paid Canadian consultant call, organize the public evidence around your product family so the conversation goes to judgment, not retrieval. The Canada / Health Canada Market-Entry Product Evidence Pack covers each of the areas below as a source-cited artifact for qualified RA/QA or consultant review.
- Product regulatory identity research
- Device class clues
- MDALL / similar licensed devices
- Licence holder landscape
- Public device descriptions
- Intended use / technology comparison where available
- Official forms / fees / guidance checklist
- Recalls and safety alerts
- Candidate QMS / risk / PMS / labeling / usability review points
- Consultant-prep questions
Every output above is a candidate review point for qualified RA/QA or consultant review — never a regulatory determination. TrueMedDevice does not determine device class, MDL/MDEL eligibility, licence outcome, compliance, safety, or effectiveness.
Background research before scoping
Open-access research guides covering the Canadian licence pathway preparation, the public safety-history sources, and the consultant-prep checklist a founder, manufacturer, or RA/QA reviewer typically runs before formal Health Canada licence application planning.
Frequently asked questions
What is MDALL?
MDALL (the Medical Devices Active Licence Listing) is Health Canada's public registry of medical devices currently or formerly licensed under the Medical Devices Regulations (SOR/98-282). MDALL is searchable by device name, manufacturer, licence number, and class. The Product Evidence Pack uses MDALL to compile a candidate similar-device shortlist for RA/QA or consultant review. MDALL records are not a determination that any specific device is suitable as a comparator for your product.
What's the difference between an MDL and an MDEL?
An MDL (Medical Device Licence) is required for manufacturers of Class II, III, and IV medical devices marketed in Canada. An MDEL (Medical Device Establishment Licence) is required for importers and distributors, and for manufacturers of Class I devices that sell directly into Canada. Which licence applies depends on device class and your firm's role in the supply chain — that determination belongs to your RA/QA team or qualified consultant in consultation with Health Canada.
Is MDSAP required for a Health Canada Medical Device Licence?
Health Canada requires manufacturers of Class II, III, and IV devices to hold a certificate from the Medical Device Single Audit Program (MDSAP) covering ISO 13485:2016. The MDSAP certificate is part of the MDL application package. MDSAP audit scope, eligibility, and certification outcomes are determined by MDSAP-recognized Auditing Organizations and Health Canada — not by the Product Evidence Pack.
How do device classes work under SOR/98-282?
Health Canada classifies medical devices into Class I, II, III, or IV based on the risk-based rules in Schedule 1 of SOR/98-282. Class I is the lowest risk; Class IV is the highest. The Product Evidence Pack surfaces candidate device-class clues from public MDALL filings and applicable classification rules. The final classification is determined when Health Canada accepts a licence application; until then, classification clues are inputs for RA/QA or consultant review.
What evidence should I bring to a Canadian regulatory consultant?
Before paid consultant hours, gather: (1) a written intended-purpose statement, (2) candidate Class I/II/III/IV clues with sources, (3) MDL vs MDEL applicability research, (4) a similar-licensed-device shortlist from MDALL with licence numbers and status, (5) a safety-history scan from Health Canada Recalls and Safety Alerts, and (6) a fees and processing-time reference. The Product Evidence Pack delivers each of these as a source-cited artifact. Class, MDL/MDEL eligibility, and submission strategy decisions remain with your RA/QA team or qualified Canadian consultant.
This is not regulatory, legal, or compliance advice. TrueMedDevice does not determine device class, MDL/MDEL eligibility, licence outcome, compliance, safety, or effectiveness. We prepare a source-backed Health Canada / MDALL / public-source evidence pack so qualified RA/QA professionals or regulatory consultants can review and decide.